Highlight
Atorvastatin treatment led to a significant reduction in quantitative MRI markers of wall enhancement, specifically the Wall Enhancement Index (WEI) and Wall Enhancement Volume Rate (WEVR), over a six-month period.
Patients receiving statins showed a marked decrease in circulating plasma levels of pro-inflammatory cytokines, including C-reactive protein (CRP), TNF-α, IL-6, and IL-1β.
